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Random setup errors can lead to erroneous prediction of the dose distribution calculated for a
patient using a static computed tomography ~CT! model. Multiple recomputations of the dose
distribution covering the range of expected patient positions provides a way to estimate a course of
treatment. However, due to the statistical nature of the setup uncertainties, many courses of treat-
ment must be simulated to calculate a distribution of average dose values delivered to a patient.
Thus, direct simulation methods can be time consuming and may be impractical for routine clinical
treatment planning applications. Methods have been proposed to efficiently calculate the distribu-
tion of average dose values via a convolution of the dose distribution ~calculated on a static CT
model! with a probability distribution function ~generally Gaussian! that describes the nature of the
uncertainty. In this paper, we extend the convolution-based calculation to calculate the standard
deviation of potential outcomes sD(x ,y ,z) about the distribution of average dose values, and we
characterize the statistical significance of this quantity using the central limit theorem. For an
example treatment plan based on a treatment protocol in use at our institution, we found that there
is a 68% probability that the actual dose delivered to any point (x,y,z) will be within 3% of the
average dose value at that point. The standard deviation also yields confidence limits on the dose
distribution, and these may be used to evaluate treatment plan stability. © 1999 American Asso-
ciation of Physicists in Medicine. @S0094-2405~99!02411-6#
Key words: patient setup uncertainty, treatment verification, treatment planning, dose calculationsI. INTRODUCTION
Uncertainties arising from daily setup errors and organ mo-
tion can lead to differences between the dose distribution on
a treatment plan and the actual dose distribution delivered to
a patient. Two primary approaches exist to account for these
uncertainties. The traditional approach measures or estimates
the extent of setup uncertainty and organ motion and adds
margins around a clinical target volume ~CTV! to form a
planning target volume ~PTV!. The dose is calculated on a
static patient model and prescribed to the PTV, with the in-
tent that the actual dose delivered to the CTV will be equiva-
lent to the predicted dose distribution. This margin expansion
approach does not account for the differences between the
predicted dose distribution and the actual delivered dose dis-
tribution for normal tissues near the CTV. The second ap-
proach includes margins for errors and incorporates the un-
certainties directly into the dose calculations, thereby giving
a more complete and accurate prediction of the delivered
dose distribution to both the target volume and normal tis-
sues.
Methods based on a convolution of the static dose distri-
bution with a function ~generally Gaussian! representing the
distribution of random uncertainties from setup and organ
motion have been proposed for sites in the pelvis.1–5 In a
previous paper, we described a convolution-based method to
incorporate uncertainties from intratreatment organ motion2397 Med. Phys. 26 11, November 1999 0094-2405/99/26due to breathing into 3-D dose calculations.6 In the present
work, we generalize this method to incorporate uncertainties
due to daily setup errors into 3-D dose calculations for ra-
diotherapy. In doing this, we quantitatively describe potential
differences between convolution-based predictions of the
dose distribution and the actual dose delivered in a finite-
fractioned course of treatment. We confirm the validity of
our approach via comparisons to direct simulations for treat-
ment of tumors in the liver. Also, we retrospectively analyze
the effects of these uncertainties on the treatment plan and
dose prescriptions based on a treatment protocol for liver
disease used at the University of Michigan.7–9
II. METHODS AND MATERIALS
The basic algorithm for convolving setup uncertainties
with a static dose distribution has been described
previously.1–5 The convolution method assumes rigid body
motion, no change in the patient external contour, and no
organ deformation. In the present study, we consider random
translational setup uncertainties along the anterior–posterior
~AP!, left–right ~LR!, and superior–inferior ~SI! axes.
Based on a retrospective analysis of our patient setup by
Schewe et al.,10 we assume that the translations along these
primary axes are independent and that the nature of the ran-
dom translational setup uncertainties can be characterized by
Gaussian probability distribution functions, as shown in Fig.239711/2397/6/$15.00 © 1999 Am. Assoc. Phys. Med.
2398 Lujan et al.: Quantization of setup 2398FIG. 1. Measured distribution of setup errors in the LR and SI directions and Gaussian model of data ~solid line! for treatments to sites in the abdomen.1 for treatment to sites in the abdomen. In this figure, the
origin of coordinates corresponds to the nominal position of
the patient assuming no systematic error ~i.e., the static pa-
tient position at treatment planning!. The mean setup uncer-
tainty is assumed to be zero for all three axes, and we used
the standard deviations in translation from Schewe’s study
(sLR57.4 mm, sAP54.9 mm, sSI55.3 mm!.
The distribution of average dose values D¯ (x ,y ,z), includ-
ing random translational setup uncertainties calculated using
a convolution-based method, is computed using Eq. ~1!:
D¯ ~x ,y ,z !5EEED0~x8,y8,z8!
3N~x82x ,y82y ,z82z ! dx8dy8dz8, ~1!
where D¯ (x ,y ,z) is the mean dose to any point x,y,z including
uncertainties; D0(x8,y8,z8) is the static dose to a point x8,
y8,z8; N is the normalized probability distribution function
describing setup uncertainties in 3-D along the LR, AP, and
SI axes, respectively; N5Nx(x82x)Ny(y82y)Nz(z82z);
and Nx(x82x)5e2(x82x)
2/2s
x
2
/sxA2p , is the normal distri-
bution with standard deviation sx about a point x, similar for
y and z.
In theory, the integration is carried out over all space
~6‘!, but for a practical implementation, we cut off the in-
tegration at 63s in each direction and renormalize. As noted
by Leong1 and Killoran,11 the distribution of average dose
values calculated using Eq. ~1! represents the dose distribu-
tion received by the patient given an infinite number of small
fractions. However, a real course of treatment is delivered
with a finite number of fractions.
Leong proposed characterizing the potential difference
between a real finite fractioned treatment and the distribution
of average dose values D¯ by the standard deviation sD of the
average dose distribution. Killoran proposed using a Monte
Carlo-based direct simulation method to account for the fi-
nite nature of treatment delivery ~a course of treatment is
simulated multiple times, allowing for the computation of the
mean dose distribution as well as a range of possible out-Medical Physics, Vol. 26, No. 11, November 1999comes about the mean dose distribution!. However, direct
simulations can be time consuming and often impractical for
regular treatment planning applications.
Hence, we extended the convolution-based method to al-
low for an efficient computation of the standard deviation sD
of the average expected dose distribution D¯ . Our method for
calculating sD and the statistical significance of this quantity
is given below.
The general expression for the standard deviation12 is
sD~x ,y ,z !5F E E E @D0~x8,y8,z8!2D¯ ~x ,y ,z !#2
3N~x82x ,y82y ,z82z ! dx8dy8dz8G1/2.
~2!
Equation ~2! can be expanded and expressed as
sD~x ,y ,z !5F S E E E D02~x8,y8,z8!
3N~x82x ,y82y ,z82z ! dx8dy8dz8 D
2~D¯ 2~x ,y ,z !!G1/2. ~3!
Equation ~3! gives the standard deviation that would result
from an entire treatment delivered in a single fraction with a
setup uncertainty characterized by N(x82x ,y82y ,z82z).
Real treatments are delivered over M multiple fractions, and
so the standard deviation for a fractionated plan is smaller
than sD by 1/AM . For a fractionated plan, the probability
that the absolute difference between a real treatment consist-
ing of M fractions DM and D¯ (x ,y ,z) at any point x,y,z will
be less than sD(x ,y ,z)/AM can be expressed using the cen-
tral limit theorem13 as
prob H uDM~x ,y ,z !2D¯ ~x ,y ,z !u,ksD~x ,y ,z !AM J
5
1
A2p
E
2k
k
e2t
2/2 dt . ~4!
2399 Lujan et al.: Quantization of setup 2399The integral on the right-hand side of Eq. ~4! ’0.68 for k
51, 0.95 for k52, and 0.98 for k53.
We performed Monte Carlo-based direct
simulations11,14–16 using the treatment planning system at the
University of Michigan ~UMPLAN, University of Michigan,
Ann Arbor, MI! to confirm the validity of our convolution-
based approach to calculate D¯ (x ,y ,z) and sD(x ,y ,z). Our
procedure is described below.
~1! Randomly sample the setup orientation for each fraction
in 3-D from the normal distributions shown in Fig. 1.
~The distribution was sampled over 63s and properly
renormalized.!
~2! Recalculate the dose distribution for each fraction in the
new geometry using the beam weights ~monitor units!
from the original configuration ~i.e., for a slightly mis-
aligned patient, treatment would proceed under original
plan assumptions, but with slightly altered patient geom-
etry!.
~3! Combine the dose distribution from each fraction on a
common grid to form one possible realization of the
course of treatment.
~4! Repeat procedure to calculate many possible realizations
of outcome.
~5! Average all realizations to determine distribution of av-
erage dose values.
~6! Calculate the distribution of standard deviation values
about the average dose values ~direct simulation includes
effects of fractionation in the calculation of standard de-
viation!.
~7! Compare the dose distribution and standard deviation
distribution to the outcome of the convolution calcula-
tions.
The treatment planning geometry used for our simulations
is shown in Fig. 2. In this problem, the gross tumor volume
~GTV! is located in the anterior–inferior portion of the liver.
We expanded the PTV from the CTV by an amount equal to
the standard deviation of the setup uncertainties in the LR,
AP, and SI directions ~i.e., LR expansion of 7.4 mm 5sLR ,
AP expansion of 4.9 mm 5sAP , SI expansion of 5.3 mm
5sSI). Organ motion due to breathing was not considered
FIG. 2. Treatment planning geometry.Medical Physics, Vol. 26, No. 11, November 1999for this study. We treated the PTV using a right lateral beam
~RL!, a posterior–anterior beam ~PA!, and a wedged pair of
oblique beams ~RAIO, LASO!. The 95% isodose surface
completely covered the PTV ~normalized to 100% at iso-
center!. Based on the dose to the normal liver ~characterized
by the effective volume Veff ,17 the fractional volume of an
organ that if uniformly irradiated would result in the same
complication probability as the nonuniform irradiated sce-
nario!, treatment delivery was planned for 58 fractions at 1.5
gray/fraction delivered twice daily.
We compared the distribution of average dose values cal-
culated using Eq. ~1! to the static ~initial treatment plan! dose
distribution. Also, we calculated dose volume histograms
~DVHs! and the effective volume Veff for the convolved and
static treatment plans to determine the gross effects of the
setup uncertainties on the treatment plan, as per a liver dose
escalation protocol.7–9 Next, we calculated the standard de-
viation of the convolved dose distribution @D¯ (x ,y ,z)# using
Eq. ~3! and evaluated the result using Eq. ~4! to determine
the range of potential outcomes in dose about the average
dose values.
The results of our convolution-based calculations were
also compared to the direct simulations, in the manner de-
scribed above. We calculated upper and lower bounds on the
dose distribution via calculation of D¯ 12sD /AM and D¯
22sD /AM , respectively ~95% confidence limits!. We then
developed an interpretation of these bounds for the dose dis-
tribution and potential applications in the reevaluation of
treatment plans using DVHs and Veff calculations.
III. RESULTS
Figure 3~a! shows the RL and PA beam orientation on a
single axial CT slice. Figure 3~b! shows a dose difference
display, in which the original planning ~static! dose distribu-
tion is subtracted from the distribution of average dose val-
ues (D¯ 2D0). Dose to the CTV predicted using a static
model is approximately the same as the distribution of aver-
age dose values that includes uncertainties, indicating that
the margins for the PTV are sufficient. Differences up to
68% of the isocenter dose are observed in regions outside
the CTV, resulting in a decrease in Veff for the normal liver
sufficient to consider a change in the prescription dose as-
signed for this treatment plan to maintain a fixed level of
toxicity.9,18
As discussed above, for comparison to the convolution-
based calculations, we performed multiple direct simulations
for the treatment plan shown in Fig. 2 ~58 fractions per
course of treatment at 1.5 gray/fraction!. Ten courses of
treatment were computed, then averaged and compared to
the distribution of average dose values D¯ calculated using
the convolution method of Eq. ~1!. A dose difference display
~not shown! demonstrated negligible differences ~,0.5%! in
the regions of interest ~normal liver, target volumes!, with
differences observed near the surface of the patient due to
artifacts in the convolution calculation arising from discon-
tinuities of the dose distribution at the patient surface. The
2400 Lujan et al.: Quantization of setup 2400DVHs for the target and organs at risk were indistinguishable
between the average of the direct simulation calculations and
the convolution-based calculation, with Veff calculations dif-
fering by less than 0.2%.
FIG. 3. ~a! Single axial slice showing RL and AP beam orientation, ~b! dose
difference display: D¯ 2D0 . The CTV contour is indicated in white. Light
gray areas indicate regions where D¯ .D0 , dark gray areas indicate regions
where D¯ ,D0 ~68%!.
FIG. 4. Dose difference display between two direct simulations of a course
of treatment consisting of 56 fractions DN and the distribution of average
dose values calculated via convolution D¯ . Differences up to 62% are ob-
served.Medical Physics, Vol. 26, No. 11, November 1999On average, the dose distribution calculated via multiple
direct simulations and convolution-based methods @Eq. ~1!#
agree ~,0.5% differences!, but the dose distribution from
any single simulation of a course of treatment DN could de-
viate from that average @Eq. ~1!#. This is shown in Fig. 4 on
a single CT slice for the treatment planning geometry in Fig.
2. For this treatment plan, we observed potential differences
between direct simulations ~58 fractions! and D¯ up to 2% in
regions outside the CTV.
Results from calculations of sD(x ,y ,z)/AM for M558
fractions are shown in Fig. 5 for axial, coronal, and oblique
CT reconstructions ~in a plane containing beams oblique
beams 3 and 4!. The spatial distribution of sD /AM com-
puted via Eq. ~3! agrees with calculations made via direct
simulations ~not shown, ,0.2% differences!.
IV. DISCUSSION
For the example shown, the PTV margins about the CTV
were sufficiently large that a realistic dose calculation includ-
ing random setup uncertainties demonstrated that the static
dose calculation correctly predicted the dose to the CTV.
FIG. 5. sD /AM for treatment geometry given in Fig. 2 on an axial, coronal,
and oblique CT reconstruction ~beam numbers indicated!.
2401 Lujan et al.: Quantization of setup 2401However, random setup uncertainties during fractionated ra-
diotherapy led to erroneous predictions of the doses to nor-
mal tissues. As seen in Fig. 3, the maximum differences
between the preplanned and average dose calculation includ-
ing predicted daily variations are in normal tissue regions
corresponding to the beam edges. This result agrees with
clinical observations made by Michalski et al.19 Though the
example shown is specific to a particular treatment planning
geometry, it is clear that including the effects of random
setup uncertainties in the dose calculations can lead to
changes in the prescription dose for protocols based on the
predicted dose distribution to normal tissues.
The distribution of average dose values D¯ (x ,y ,z) can be
calculated via direct simulations of the treatment, or when
appropriate, via a convolution-based calculation applied to
the static dose distribution @Eq. ~1!#. In both cases, D¯ (x ,y ,z)
represents the dose to points x,y,z that would be delivered to
an average patient given a very large ~infinite! number of
fractions. The dose delivered in a finite-fractioned treatment
can differ from D¯ for even a relatively large number of frac-
tions.
FIG. 6. sD /AM for 10 ~a!, 20 ~b!, and 40 fractions ~c! on a single axial CT
slice.Medical Physics, Vol. 26, No. 11, November 1999We have proposed a method to calculate the range of
potential outcomes in a real treatment about D¯ (x ,y ,z) using
a convolution-based calculation. Using the central limit theo-
rem, this distribution of possible outcomes can be character-
ized by sD(x ,y ,z)/AM @where the standard deviation
sD(x ,y ,z) is defined in Eq. ~3!, and M is the number of
fractions in a course of treatment#. Calculation of D¯ (x ,y ,z)
62sD(x ,y ,z)/AM can provide population-based confidence
limits on our dose distribution ~in particular for dose to sen-
sitive structures! and should be considered when assigning
the prescription dose.
While the upper and lower bounds on the dose distribu-
tion represent true 95% confidence limits ~based on the cen-
tral limit theorem!, the upper bound assumes that all points
in the distribution receive a dose greater than the average
dose, while the lower bound assumes that all points receive a
dose smaller than the average dose. These bounds may not
be physically realizable because of conservation of energy
~delivered dose! ~i.e., if some points in the dose distribution
receive a higher than average dose, then other points will
receive a lower than average dose!. Thus, the upper and
lower bounds are true on a voxel-by-voxel basis but do not
generally represent the physical ~realizable! upper and lower
bounds on the total dose distribution. Hence, the spatial dis-
tribution of sD(x ,y ,z)/AM should be considered when
evaluating the upper and lower bounds on the average dose
distribution D¯ (x ,y ,z).
As the number of fractions in the treatment plan increases,
the range of potential outcomes about the average outcome
will decrease. This is shown in Fig. 6, where the distribution
of sD(x ,y ,z)/AM is compared for M510, 20, and 40 frac-
tions using the planning geometry described in Fig. 2. This is
also seen in Fig. 7, which shows cumulative DVHs of the
normal liver based on calculations of D¯ and D¯ 62sD /AM
for 10 and 40 fractions. Clearly, as the number of fractions
increases, D¯ become a better prediction of the actual dose
delivered to the patient.
As noted earlier, the convolution calculation does not
FIG. 7. Cumulative DVH of the normal liver for D¯ and D¯ 62(sD /AM ) for
10 and 40 fractions.
2402 Lujan et al.: Quantization of setup 2402agree with direct simulations near the patient surface. In gen-
eral, a convolution-based approach is not valid in regions
where the dose distribution itself is not invariant under small
changes, for example, near interfaces with large homogene-
ity differences ~lung/normal tissue interface, external surface
of the patient!. Based on our algorithm ~in which the convo-
lution is performed over 63s), the average dose distribu-
tion calculated via Eq. ~1! is not accurate in regions within
3s distance of such an interface, and care must be taken in
evaluating the dose to volumes in those regions.
In regions where Eq. ~1! can be applied, calculation of
D¯ (x ,y ,z) and sD(x ,y ,z)/AM can be used to evaluate the
stability of a treatment plan. For example, beam angles that
may lead to unacceptable variations in dose to normal tissues
can be adjusted as necessary. Further, setup situations that
may require additional efforts ~such as daily portal imaging!
to minimize setup uncertainties can be identified.
Finally, for a single patient geometry, alternative treat-
ment plans can be evaluated in terms of the effects uncer-
tainties have on the plan. As an example, a second treatment
plan was designed for the same patient geometry as Fig. 2.
The PTV for the second treatment plan was covered by the
95% isodose surface using three oblique beams. Treatment
delivery was planned using the same fractionation scheme
~58 fractions at 1.5 gray/fraction! as plan 1 ~Fig. 2!. The
distribution of sD(x ,y ,z)/AM was calculated for plan 2 and
compared to plan 1 as shown in Fig. 8. The range of possible
outcomes about the average expected dose distribution is
smaller for treatment plan 1 than for treatment plan 2. Hence,
all other factors being equal, we would prefer treatment plan
1, as we are better able to predict the dose to the patient for
plan 1 compared with plan 2.
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